Lv11
12 积分 2021-08-23 加入
Intrinsic electrical activity drives small-cell lung cancer progression
5小时前
待确认
A Meta-Analysis Assessing the Therapeutic Efficacy and Safety of Anlotinib in Combination with Chemotherapy for Small Cell Lung Cancer
29天前
已完结
The efficacy and safety of anlotinib for subsequent line treatment of small cell lung cancer: a systematic review and meta-analysis
29天前
已完结
Safety and efficacy of anlotinib in combination with standard chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A multi-center, prospective study (ACTION-2)
29天前
已完结
Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study
29天前
已完结
Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer
29天前
已完结
Overall Survival (OS) Update in ALTER 1202: Anlotinib as Third-Line or Further-Line Treatment in Relapsed Small-Cell Lung Cancer (SCLC)
1个月前
已完结
Tarlatamab: First Approval
1个月前
已完结
Top advances of the year: Small cell lung cancer
1个月前
已完结
First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors
2个月前
已完结
皖公网安备34019202002308
